

## Reproducibility of ADC in colorectal liver metastases at 3T: a cross-vendor evaluation

Sabrina Doblas<sup>1</sup>, Philippe Garteiser<sup>1</sup>, Vincent Barrau<sup>2,3</sup>, Magaly Zappa<sup>1,2</sup>, Valérie Vilgrain<sup>1,2</sup>, and Bernard E Van Beers<sup>1,2</sup>

<sup>1</sup>U1149 - CRI, INSERM, Paris, France, <sup>2</sup>Radiology, Beaujon Hospital, Clichy, France, <sup>3</sup>CCN, Saint-Denis, France

**Purpose:** Diffusion-weighted imaging (DWI) represents an important tool in the evaluation of colorectal liver metastases. Measurements of diffusion parameters in this tumor type have been recently proposed to assess tumor necrosis<sup>1</sup> and predict<sup>2-4</sup> or assess treatment response<sup>5,6</sup>. Reproducibility studies at 1.5T yielded reproducibility in the order of 20% for the apparent diffusion coefficient (ADC), sufficient for determining parameter changes in recently treated lesions<sup>7</sup>. Despite the increasing number of 3T clinical systems, the reproducibility of ADC in liver tumors at 3T has only been assessed in few studies<sup>8</sup>, and, to date, the specific cases of colorectal liver metastases and inter-vendor reproducibility have not yet been evaluated. The aim of our study was to assess the reproducibility of ADC at 3T in liver metastases of colorectal cancer in a two-center, cross-vendor configuration.

**Methods:** The study was carried out on two 3T MRI systems (Philips and GE). Five patients (4 men, 1 woman, bearing 19 tumors > 1cm) were recruited on the GE system, and 6 patients (5 men, 1 woman, bearing 27 tumors > 1cm) were recruited on the Philips system. Two acquisition protocols were applied and, for each protocol, acquisition was repeated to yield test-retest DWI data. Protocol A was a standard clinical DWI protocol with 4 b-values (0, 150, 400 and 800 s/mm<sup>2</sup>), while protocol B had an extended b-space coverage (0, 10, 20, 30, 50, 75, 100, 150, 400, 800 s/mm<sup>2</sup>). Both yielded ADC measurements with a monoexponential fit over all b values. Protocols were otherwise matched for number of signal averages (4), free breathing, acquisition resolution (1.4-1.5 mm), slice thickness (5 mm), TR (> 5000ms) and TE (< 70ms). Data were analyzed in terms of mean ADC over the whole tumor. Bias and coefficients of reproducibility (CR) were calculated from the Bland-Altman plots and compared with Levene's tests.

**Results:** *Protocol A:* the Philips system yielded almost no bias, with CR of 23% similar to typical literature figures at 1.5T. The GE system had a weak positive bias (3%), and reproducibility was similar (CR = 18.5%). *Protocol B:* The Philips and the GE systems had similar measurement bias (2% and -2%, respectively) and similar CR (15.5% and 13.2%, respectively). Protocol B yielded better reproducibility than protocol A ( $p = 0.034$ ).

**Conclusions:** Reproducibility of ADC in colorectal liver metastases at 3T was similar between vendors and comparable to previously reported figures at 1.5T. The best reproducibility was obtained with the extended b space coverage acquisition protocol. The good reproducibility results of our study suggest that the assessment of ADC changes during treatment at 3T in colorectal liver metastases is feasible in a multicenter, multi vendor context.




Figure 1: Representative ADC maps overlaid on anatomical images for Philips system (top) and GE system (bottom) for the initial scan (left) and the repeated scan (right). Insets: ADC histograms of the respective tumors




Figure 2: Bland-Altman plots of the test-retest results. Repeatability is comparable between vendors. The monoexponential model analysis of 10 b values data yields the best results.

## References:

1. Chiaradia M. *et al. J Magn Reson Imaging* 2014 ; 39(2) : 317
2. Szurowska E. *et al. J Magn Reson Imaging* 2013; 38(5): 1027
3. Wybranski C. *et al. Radiat Oncol* 2011, 6(1): 43
4. Dudeck O. *et al. Eur Radiol* 2010; 20(11): 2699
5. Anzidei M. *et al. J Comput Assist Tomogr* 2011; 35(6): 690
6. Marugami N. *et al. Cardiovasc Intervent Radiol* 2009; 32(4): 638
7. Heijmen L. *et al. Eur Radiol* 2013 ; 23(3) : 748
8. Larsen N.E. *et al. MAGMA* 2013; 26(5): 431